Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled …
AM Hoffmann-Vold, ER Volkmann… - The Lancet …, 2022 - thelancet.com
Background Nintedanib is a tyrosine kinase inhibitor used in the treatment of progressive
fibrosing interstitial lung diseases (ILDs). We assessed the safety and tolerability of …
fibrosing interstitial lung diseases (ILDs). We assessed the safety and tolerability of …
Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled …
ER Volkmann, DP Tashkin, R Silver… - The Lancet …, 2022 - thelancet.com
Background Observational studies have shown that men with systemic sclerosis have an
increased risk of interstitial lung disease (ILD) and mortality compared with women …
increased risk of interstitial lung disease (ILD) and mortality compared with women …
Sex and gender-based analysis and diversity metric reporting in acute care trials published in high-impact journals: a systematic review
Objective To characterise sex and gender-based analysis (SGBA) and diversity metric
reporting, representation of female/women participants in acute care trials and temporal …
reporting, representation of female/women participants in acute care trials and temporal …
The future of PAH treatment
JL Keen, N Al-Naamani… - Advances in Pulmonary …, 2023 - meridian.allenpress.com
Pulmonary arterial hypertension (PAH) is a devastating disease mediated by
vasoconstriction and vascular remodeling of the pulmonary vasculature. Current therapies …
vasoconstriction and vascular remodeling of the pulmonary vasculature. Current therapies …